体重校正对唐氏综合征筛查风险计算的影响。
The effect of weight correction on risk calculations for Down's syndrome screening.
作者信息
Reynolds T M, Penney M D, Hughes H, John R
机构信息
Medical Biochemistry Department, University Hospital of Wales, Heath Park, Cardiff, UK.
出版信息
Ann Clin Biochem. 1991 May;28 ( Pt 3):245-9. doi: 10.1177/000456329102800308.
Recent advances in prenatal screening have led to the possibility that the risk of Down's syndrome associated pregnancy may be assessed by blood tests for maternal serum alphafetoprotein, human chorionic gonadotrophin (and possibly unconjugated oestriol) taken at 15-18 weeks of gestation. In neural tube defect screening correction of maternal serum alphafetoprotein for maternal weight has been recommended, although the precise method for weight correction is still under debate. We report an assessment of weight correction for maternal serum alphafetoprotein and human chorionic gonadotrophin based on 1408 singleton pregnancies and for unconjugated oestriol based on 197 singleton pregnancies. We demonstrate that weight correction of maternal serum alphafetoprotein and human chorionic gonadotrophin is statistically valid but that correction of unconjugated oestriol is not.
产前筛查的最新进展使得在妊娠15至18周时通过检测孕妇血清甲胎蛋白、人绒毛膜促性腺激素（可能还有非结合雌三醇）的血液检查来评估唐氏综合征相关妊娠风险成为可能。在神经管缺陷筛查中，尽管体重校正的确切方法仍在讨论中，但已建议对孕妇血清甲胎蛋白进行孕妇体重校正。我们报告了基于1408例单胎妊娠对孕妇血清甲胎蛋白和人绒毛膜促性腺激素进行体重校正的评估，以及基于197例单胎妊娠对非结合雌三醇进行体重校正的评估。我们证明，对孕妇血清甲胎蛋白和人绒毛膜促性腺激素进行体重校正在统计学上是有效的，但对非结合雌三醇进行校正则无效。
Zotero 插件